A recent study has shown that patients with relapsed or refractory chronic lymphocytic leukemia may prolong their progression-free survival after treatment with a specific combination regimen. READ MORE
The FDA just announced that it will allow marketing of the first agency-authorized test for use with flow cytometry in order to help in the detection of several leukemias and lymphomas.
Adolescent and young adult survivors of Hodgkin lymphoma may not be receiving the recommended post-treatment care.
A recent study has shown that patients with relapsed or refractory chronic lymphocytic leukemia may prolong their progression-free survival after treatment with a specific combination regimen.
Researchers have developed a novel prognostic assay that identifies patients with Hodgkin lymphoma with unfavorable post-ASCT outcomes after relapse.
The U.S. Food and Drug Administration said on Thursday it has approved Bayer AG’s treatment for follicular lymphoma, a cancer of the lymph system.
Jennifer R Brown, MD, PhD, presented the emerging treatments and management options for front line and relapsed or refractory chronic lymphocytic leukemia today at the Clinical Pathways Congress.
Research in Review
A recent study suggests a variable that should be used as a standard outcome measure for clinical trials of patients with follicular lymphoma.
Recent research in the Journal of Clinical Oncology examined outcomes for patients with myeloid malignancies who had vitamin D deficiency before undergoing allogeneic stem cell transplantation.
Addition of a multi-targeted kinase inhibitor to standard chemotherapy improves outcomes in patients with acute myeloid leukemia and a specific mutation.
Single-agent immunotherapy in patients with a subtype of diffuse large B-cell lymphoma provides more clinical benefit than conventional therapy.